Abeona Therapeutics Independent Director Mark Alvino Sells 41% Of Holding
Abeona Therapeutics Independent Director Mark Alvino Sells 41% Of Holding
We'd be surprised if Abeona Therapeutics Inc. (NASDAQ:ABEO) shareholders haven't noticed that the Independent Director, Mark Alvino, recently sold US$117k worth of stock at US$4.51 per share. That sale was 41% of their holding, so it does make us raise an eyebrow.
如果您是Abeona therapeutics（纳斯达克ABEO）的股东，您就会惊讶地发现，独立董事Mark Alvino最近以每股4.51美元的价格出售了价值117,000美元的股票。这次交易占他们所持股份的41%，让我们开始警惕。
The Last 12 Months Of Insider Transactions At Abeona Therapeutics
Abeona Therapeutics最近12个月内的内部交易情况
Notably, that recent sale by Mark Alvino is the biggest insider sale of Abeona Therapeutics shares that we've seen in the last year. That means that even when the share price was slightly below the current price of US$4.58, an insider wanted to cash in some shares. We generally consider it a negative if insiders have been selling, especially if they did so below the current price, because it implies that they considered a lower price to be reasonable. Please do note, however, that sellers may have a variety of reasons for selling, so we don't know for sure what they think of the stock price. We note that the biggest single sale was only 41% of Mark Alvino's holding.
值得注意的是，Mark Alvino最近的交易是Abeona Therapeutics股票中我们在去年看到的最大的内部交易之一。这意味着即使股价略低于当前价格4.58美元，内部人士仍想套现一些股票。如果内部人士以低于当前价格出售，我们通常认为是负面的，因为这意味着他们认为更低的价格是合理的。请注意，卖方可能有各种各样的原因出售股票，所以我们不能确定他们对股票价格的看法。我们注意到最大的单笔交易仅占Mark Alvino所持股份的41%。
In the last twelve months insiders purchased 88.76k shares for US$346k. But they sold 92.85k shares for US$411k. In total, Abeona Therapeutics insiders sold more than they bought over the last year. The average sell price was around US$4.43. We don't gain confidence from insider selling below the recent share price. Of course, the sales could be motivated for a multitude of reasons, so we shouldn't jump to conclusions. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
在过去12个月中，内部人士购买了88.76k股，价值346,000美元。但他们卖出了92.85k股，价值411,000美元。总的来说，Abeona therapeutics内部人士卖出的股票比买入的股票还要多。平均卖出价格约为4.43美元。内部人士低于最近的股票价格卖出不会增强我们的信心。当然，这些销售可能是出于许多原因的动机，所以我们不应该做出任何结论。下面是过去12个月（按公司和个人）内部交易的可视化描述，如果您想知道谁以多少价格在什么时候卖出，请单击下面的图表！
If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).
如果你喜欢购买内部人员正在购买而不是销售的股票，那么你可能会喜欢这份免费的公司列表。（提示：它们中的大部分都被忽视了。）
Insider Ownership Of Abeona Therapeutics
Abeona therapeutics股权内部情况
For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 3.2% of Abeona Therapeutics shares, worth about US$6.0m, according to our data. Whilst better than nothing, we're not overly impressed by these holdings.
对于普通股东来说，了解公司内部人士持有的股票数量是值得的。高比例的内部人士持有通常会使公司领导更加关注股东的利益。根据我们的数据，内部人士拥有Abeona therapeutics的3.2%股份，价值约600万美元。虽然这比没有强，但我们对这些持股并不是很印象深刻。
So What Do The Abeona Therapeutics Insider Transactions Indicate?
Abeona therapeutics内部交易的意义是什么？
The stark truth for Abeona Therapeutics is that there has been more insider selling than insider buying in the last three months. And our longer term analysis of insider transactions didn't bring confidence, either. When you combine this with the relatively low insider ownership, we are very cautious about the stock. So we'd only buy after very careful consideration. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Abeona Therapeutics. Every company has risks, and we've spotted 6 warning signs for Abeona Therapeutics (of which 3 are significant!) you should know about.
对于Abeona therapeutics来说，在过去三个月内，内部卖出的数量已超过内部买入的数量。我们对内部交易的长期分析也没有带来信心。当您将此与相对较低的内部所有权相结合时，我们对股票非常谨慎。因此，我们只会在非常仔细地考虑之后进行购买。除了了解正在进行的内部交易外，确定Abeona therapeutics可能面临的风险也很有益。每家公司都有风险，我们已经在Abeona therapeutics（其中3个是重要的！）中发现了6个警告信号，您应该了解。
But note: Abeona Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
请注意：Abeona therapeutics可能不是最佳的购买股票。因此，请查看此具有高roe和低债务的有趣公司的免费列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
对于本文而言，内部人是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置，但不包括衍生交易或间接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈？关于内容有所顾虑？直接和我们联系。或者，发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论，只使用公正的方法论，我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议，也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意，我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈？关于内容有所顾虑？直接和我们联系。或者发送电子邮件至editorial-team@simplywallst.com。